LambdaTest launches mobile application performance analytics
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has launched a slew of features to enable businesses to test the performance of their mobile apps.
Customers who are using LambdaTest’s cutting-edge real devices cloud can now test for performance metrics like CPU consumption, memory (RAM) consumption, battery usage, heat radiation, rendering/frame rate, network usage, and application start time, among others.
For example, the CPU is responsible for carrying out all the operations in a mobile device and a high usage by a single app can affect other running services. This also leads to increased battery usage. Businesses can now identify and address areas that are responsible and ensure better efficiency of the app.
Similarly, memory consumption metrics–Memory Consumed by the system (in MB) throughout the session, Memory Consumed by the application (in MB) throughout the session, Memory Available for use (in MB) throughout the session–will help development teams identify areas of the application that may be causing memory leaks. These leaks can cause the application to consume more memory over time, leading to decreased performance and crashes.
“Digital-first customers want the best overall experience out of an app and this isn’t just restricted to the in-app experience. These tech-savvy customers keep a keen eye on battery usage, heat radiation, CPU and RAM consumption, among other things. One just has to look at the reviews on Apple App Store or Google Play Store to know how important tracking these metrics is. Our goal at LambdaTest is to enable businesses with all the features that could help them test right, ultimately resulting in a great digital experience to their end customers,” said Mayank Bhola, Co-founder and Head of Product, LambdaTest.
LambdaTest also recently announced the launch of its digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options–Public cloud, single tenant, or on-premise.
To learn more, visit: https://www.lambdatest.com/support/docs/appium-app-performance-analytics
About LambdaTest
LambdaTest is an intelligent unified digital experience testing cloud that helps businesses drastically reduce time to market through faster test execution, ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
Continuous Testing Cloud
LambdaTest's Continuous Testing Cloud allows enterprises to rapidly test and deploy changes to their web and mobile applications up to 70% faster, which helps to accelerate the development process and improve time-to-market.
Cross-browser Testing Cloud
Our cross-browser testing cloud allows users to test their websites and web applications on a wide variety of browsers, operating systems, and devices. With features such as real-time testing, responsive design testing, and debugging tools, it enables developers to ensure that their websites and web apps are compatible with different browsers, thereby providing a seamless user experience.
Real Device Cloud
With real device cloud, testers/developers can catch bugs early before their mobile apps go live. With LambdaTest's Real Devices Testing Cloud, teams can test unhandled errors, UI/UX, performance, and functionality of their apps before they get released into production. The teams can also test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV).
AI-powered Visual Regression Cloud
Ensuring consistent layouts, designs, and functionality of applications is crucial to deliver visually-perfect digital experiences. LambdaTest's visual regression cloud ensures that the visual appearance and functionality of an organization’s web applications remain consistent and error-free, ultimately improving the digital experience and business performance. Teams can get early insights on visual UI bugs before they release their applications to the customer. Testers/developers can run automated visual regression tests on 3000+ combinations of browsers & real devices to identify visual deviations.
AI-powered Integrated Test Intelligence
Test execution insights are critical for digital transformation as they provide enterprises with deeper insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's integrated test intelligence provides enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality. This can empower development teams with detailed and actionable test execution data and close the gap between data, insight, and action for better and faster decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005797/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom